Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that Michael D. Taylor, Ph.D., President and Chief Executive Officer, will present at the 30th Annual Piper Jaffray Healthcare Conference on Tuesday, November 27, 2018 at 2:30 PM ET at the Lotte New York Palace Hotel.
A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/news-events/events-presentations. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is
a clinical-stage biopharmaceutical company focused on improving the
lives of cancer patients by tackling key mechanisms of drug resistance
that limit the rate and/or durability of response to existing cancer
therapies. Our small molecule drug candidates are directed against an
important family of enzymes called kinases, known to be directly
involved in the growth and spread of many cancers. We use our deep
understanding of kinase biology together with a proprietary chemistry
library to purposefully design compounds that maintain kinases in a
“switched off” or inactivated conformation. These investigational
therapies comprise tumor-targeted agents designed to address therapeutic
resistance causing mutations and immuno-targeted agents designed to
control the activation of immunokinases that suppress critical immune
system regulators, such as macrophages. We have used our platform to
develop a diverse pipeline of tumor-targeted and immuno-targeted drug
candidates designed to improve outcomes for patients with cancer by
improving the quality, rate and/or durability of their responses to
treatment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181120005133/en/
Media:
Gina Nugent, The Yates Network
[email protected]
617-460-3579
Investor Relations:
Laura Perry or Sam Martin, Argot Partners
[email protected]
or [email protected]
212-600-1902
Company:
Christopher J. Morl, Chief Business Officer
Deciphera
Pharmaceuticals, Inc.
[email protected]
781-209-6418